International Liver Congress

International Liver Congress

Source:

Canillas L, et al. Abstract OS-1921. Presented at: the International Liver Congress; June 23-26 (virtual meeting).

Disclosures: Healio was unable to confirm relevant financial disclosures at the time of publication.
July 08, 2021
1 min read
Save

COVID-19 severity links to abnormality in liver function tests

Source:

Canillas L, et al. Abstract OS-1921. Presented at: the International Liver Congress; June 23-26 (virtual meeting).

Disclosures: Healio was unable to confirm relevant financial disclosures at the time of publication.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Among patients hospitalized with COVID-19, liver impairment appeared within the first days of admission; virus severity also correlated with abnormality in liver function tests.

“In terms of liver involvement [in COVID-19], liver function test (LFT) abnormalities are frequent and the most common is an increase of aspartate aminotransferase. Moreover, most of the LFT abnormalities are minor and less than 20% exceeded the upper limit of abnormality,” Lidia Canillas, Hospital del Mar in Barcelona, Spain, said. “Severe LFT abnormalities have been related to more severe infection; to our knowledge, no data about the evolution of LFTs electives and liver damage at the resolution of acute infection have been reported so far.”

Highlighted liver
Source: Adobe Stock

In a retrospective, observational study, researchers analyzed 595 patients hospitalized with COVID-19 (mean age 62 years; 60.7% men) to evaluate factors related to LFT abnormality amid COVID-19. They determined abnormality grade (1-4) using AST, alanine aminotransferase and total bilirubin levels; additional recorded assessments included sociodemographic data, comorbidities, COVID-19 infection severity, laboratory tests, treatments and mortality. Researchers noted severe COVID-19 in 42% of patients.

Study results revealed LFT abnormality in 61.5% of patients with grade 1, 38.8% of patients with grade 2, 11.8% of patients with grade 3 and 10.3% of patients grade 4. Among patients with severe LFT, abnormality varied between mild (64.5%) and severe (35.5%) at hospital admission with the median onset of maximum LFT impairment at 12-days from hospital admission. Further multivariate analysis revealed LFT abnormality correlated with higher interleukin-6 (1.63; 1.01-2.62) and ferritin (2.68; 1.64-4.37); worsened LFTs during hospital admission correlated with ICU admission (5.34; 3.08-9.28) and use of immunomodulatory drugs (2.57; 1.5-4.39). Mortality within this cohort was 10.7%.

“The presence of abnormal LFTs at follow-up was not related to abnormal LFTs during COVID-19 hospital admission,” Canillas concluded. “Patients with altered LFTs at follow-up have an underlying cause, most of them fatty liver disease.”